FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2759349664> ?p ?o ?g. }

• W2759349664 endingPage "427" @default.
• W2759349664 startingPage "420" @default.
• W2759349664 abstract "Abstract Background EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque‐type psoriasis as a part of totality of evidence gathered during the development of GP 2015, an etanercept biosimilar. Objective To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP 2015 and the etanercept originator product ( ETN , Enbrel ® ) and evaluate effects of repeated switching between GP 2015 and ETN . Results for efficacy, safety and immunogenicity during treatment period ( TP ) 2 ( TP 2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). Methods Patients ( n = 531) were randomized 1:1 to self‐administer GP 2015 or ETN twice‐weekly subcutaneously during TP 1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index ( PASI 50) at week 12 were re‐randomized for TP 2 to continue the same treatment at once‐weekly dosing or to undergo three consecutive treatment switches between GP 2015 and ETN until week 30. Patients continued the last‐assigned treatment during TP 2, until week 52. Results Mean (standard deviation [ SD ]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP 2. During TP 2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment‐emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti‐drug antibodies in TP 2. Conclusion Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP 2, indicating that there are no effects in the short term on clinical data of multiple switches between GP 2015 and ETN ." @default.
• W2759349664 created "2017-10-06" @default.
• W2759349664 creator A5004373858 @default.
• W2759349664 creator A5033251316 @default.
• W2759349664 creator A5034356416 @default.
• W2759349664 creator A5047430560 @default.
• W2759349664 creator A5068353611 @default.
• W2759349664 creator A5081251444 @default.
• W2759349664 creator A5085831636 @default.
• W2759349664 creator A5091813375 @default.
• W2759349664 date "2017-11-02" @default.
• W2759349664 modified "2023-10-10" @default.
• W2759349664 title "Multiple switches between <scp>GP</scp>2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory <scp>EGALITY</scp> study" @default.
• W2759349664 cites W1971471395 @default.
• W2759349664 cites W2017932566 @default.
• W2759349664 cites W2030066420 @default.
• W2759349664 cites W2096991001 @default.
• W2759349664 cites W2110732019 @default.
• W2759349664 cites W2125843974 @default.
• W2759349664 cites W2155591144 @default.
• W2759349664 cites W2169911848 @default.
• W2759349664 cites W2198471696 @default.
• W2759349664 cites W2415679102 @default.
• W2759349664 cites W2543281533 @default.
• W2759349664 cites W2581281042 @default.
• W2759349664 cites W2584947097 @default.
• W2759349664 cites W2761883790 @default.
• W2759349664 doi "https://doi.org/10.1111/jdv.14605" @default.
• W2759349664 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5887937" @default.
• W2759349664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28960486" @default.
• W2759349664 hasPublicationYear "2017" @default.
• W2759349664 type Work @default.
• W2759349664 sameAs 2759349664 @default.
• W2759349664 citedByCount "69" @default.
• W2759349664 countsByYear W27593496642017 @default.
• W2759349664 countsByYear W27593496642018 @default.
• W2759349664 countsByYear W27593496642019 @default.
• W2759349664 countsByYear W27593496642020 @default.
• W2759349664 countsByYear W27593496642021 @default.
• W2759349664 countsByYear W27593496642022 @default.
• W2759349664 countsByYear W27593496642023 @default.
• W2759349664 crossrefType "journal-article" @default.
• W2759349664 hasAuthorship W2759349664A5004373858 @default.
• W2759349664 hasAuthorship W2759349664A5033251316 @default.
• W2759349664 hasAuthorship W2759349664A5034356416 @default.
• W2759349664 hasAuthorship W2759349664A5047430560 @default.
• W2759349664 hasAuthorship W2759349664A5068353611 @default.
• W2759349664 hasAuthorship W2759349664A5081251444 @default.
• W2759349664 hasAuthorship W2759349664A5085831636 @default.
• W2759349664 hasAuthorship W2759349664A5091813375 @default.
• W2759349664 hasBestOaLocation W27593496641 @default.
• W2759349664 hasConcept C126322002 @default.
• W2759349664 hasConcept C159654299 @default.
• W2759349664 hasConcept C16005928 @default.
• W2759349664 hasConcept C168563851 @default.
• W2759349664 hasConcept C197934379 @default.
• W2759349664 hasConcept C203014093 @default.
• W2759349664 hasConcept C2777011040 @default.
• W2759349664 hasConcept C2777226972 @default.
• W2759349664 hasConcept C2777288759 @default.
• W2759349664 hasConcept C2777575956 @default.
• W2759349664 hasConcept C2780564577 @default.
• W2759349664 hasConcept C2780868878 @default.
• W2759349664 hasConcept C59491497 @default.
• W2759349664 hasConcept C71924100 @default.
• W2759349664 hasConceptScore W2759349664C126322002 @default.
• W2759349664 hasConceptScore W2759349664C159654299 @default.
• W2759349664 hasConceptScore W2759349664C16005928 @default.
• W2759349664 hasConceptScore W2759349664C168563851 @default.
• W2759349664 hasConceptScore W2759349664C197934379 @default.
• W2759349664 hasConceptScore W2759349664C203014093 @default.
• W2759349664 hasConceptScore W2759349664C2777011040 @default.
• W2759349664 hasConceptScore W2759349664C2777226972 @default.
• W2759349664 hasConceptScore W2759349664C2777288759 @default.
• W2759349664 hasConceptScore W2759349664C2777575956 @default.
• W2759349664 hasConceptScore W2759349664C2780564577 @default.
• W2759349664 hasConceptScore W2759349664C2780868878 @default.
• W2759349664 hasConceptScore W2759349664C59491497 @default.
• W2759349664 hasConceptScore W2759349664C71924100 @default.
• W2759349664 hasIssue "3" @default.
• W2759349664 hasLocation W27593496641 @default.
• W2759349664 hasLocation W27593496642 @default.
• W2759349664 hasLocation W27593496643 @default.
• W2759349664 hasLocation W27593496644 @default.
• W2759349664 hasOpenAccess W2759349664 @default.
• W2759349664 hasPrimaryLocation W27593496641 @default.
• W2759349664 hasRelatedWork W1970401331 @default.
• W2759349664 hasRelatedWork W1973307523 @default.
• W2759349664 hasRelatedWork W2018438415 @default.
• W2759349664 hasRelatedWork W2058650537 @default.
• W2759349664 hasRelatedWork W2074205207 @default.
• W2759349664 hasRelatedWork W2102534587 @default.
• W2759349664 hasRelatedWork W2152281374 @default.
• W2759349664 hasRelatedWork W2186026439 @default.
• W2759349664 hasRelatedWork W2416464647 @default.
• W2759349664 hasRelatedWork W2783124138 @default.
• W2759349664 hasVolume "32" @default.
• W2759349664 isParatext "false" @default.

• next